Here are the 10-K annual reports from Schrodinger, Inc. (SDGR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SDGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SDGR filings page.
Schrödinger, Inc. uses a physics-based computational platform to speed discovery of new drugs and materials. In 2025 it generated total revenue of $255.9 million and recorded a net loss of $103.3 million, reflecting continued investment in R&D and platform growth.
Software remains the core business, with software revenue of $199.5 million, up 11% year over year, and annual contract value of $198.5 million. All top 20 global pharma companies by 2024 revenue licensed its tools, underscoring broad industry adoption.
The company deepened partnerships, including a major collaboration with Novartis that brought a $150.0 million upfront payment and up to $2.272 billion in potential milestones across initial programs. Additional collaborations with BMS, Lilly and Otsuka add future milestone and royalty potential.
Schrödinger is advancing proprietary drug candidates such as MALT1 inhibitor SGR‑1505 and Wee1/Myt1 inhibitor SGR‑3515 in Phase 1 trials, while it discontinued CDC7 inhibitor SGR‑2921 after safety concerns. Management plans to seek partners for later-stage development while focusing internally on early discovery and its growing software franchise.